Abiomed receives approval for expanded FDA indication for cardiomyopathy
Abiomed announced it has received an expanded FDA Pre-Market Approval for its Impella 2.5®, Impella CP®, Impella 5.0® and Impella LD® heart pumps to provide treatment for heart failure associated with cardiomyopathy leading to cardiogenic shock. February 13, 2018